Latest news and upcoming events

09 Sep 2021

Ysios Capital achieves Certification under the Diversity VC Standard

Upcoming events
  • Jefferies London Healthcare Conference
    16 November – 18 Nov. 2021,

  • LSX World Congress
    8 February – 9 February 2022,

ONA Therapeutics Strengthens Scientific Leadership Team

Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development.

VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001

Funding comprises grant financing of up to €2.5 million and up to €15 million in equity investment

CorWave Wins 2021 HealthTech Award

CorWave received the Medtech Award, which recognizes a medical device or diagnostic company that has distinguished itself over the past two years.

Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

Mr. Myers will serve as a Class III director, and join both the Compensation and Nominating and Corporate Governance Committee

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

FDA has granted ODD for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

There have been no related serious adverse events, dose limiting toxicities, or grade 3 adverse events observed during the study.

Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)

This venture debt operation is supported by the European Guarantee Fund (EGF) — part of the €540 billion EU response to the economic impact of COVID-19.

Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

This study confirms our previous findings and the clinical utility of MAF Test® as a unique tool for precision medicine in early breast cancer.

Aura Biosciences Expands Executive Leadership Team and Board of Directors

Appointment of Chris Primiano, J.D., as Chief Business Officer and the appointment of Antony Mattessich to its Board of Directors.


Subscribe to our weekly newsletter for the latest
updates on life sciences investments.